BioSpace News Archive

Lena Winstedt, PhD, Head of Science at Hansa Biopharma, presented positive results from a pooled analysis of Phase 2 trials with imlifidase for desensitization in sensitized kidney transplant patients

The Alzheimer’s Research and Prevention Foundation’s Brain Longevity Therapy Training and Symposium has been approved for extensive CEU hours and CE credits.

Breakfast symposium and conference activities to highlight capabilities of vascular robotic technology and advancements in automation and remote treatment

The NCSBN Nursys e-Notify database has reached the milestone of enrolling one million nurses by institutions.

The Arizona Bioindustry Association (AZBio) today announced that Martha A. Brumfield, PhD, Special Advisor to the CEO and past President and CEO at the Critical Path Institute (C-Path), will be honored as the Jon W. McGarity Arizona Bioscience Leader of the Year at the 2019 AZBio Awards on October 2, 2019, at the Phoenix Convention Center.

IQVIA™ (NYSE:IQV) is proud to announce its collaboration with Friends of Cancer Research in a cross-industry effort to advance acceptance and drive future uses of real world evidence (RWE).

CoreLink, LLC, a leading designer and manufacturer of spinal implant systems, today announced the introduction of the Oro™ Lateral Plate System designed for optimum versatility to treat patients suffering from degenerative disk disease, spondylolisthesis, trauma, or spinal deformities.

Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic medicines company leveraging its proprietary hyaluronic acid (“HA”) technology platform to provide therapies across the Joint Preservation and Restoration continuum of care, today announced it has commenced the U.S. commercial soft launch of TACTOSET, its injectable HA-enhanced bone repair therapy

Graybug Vision, Inc., a clinical stage pharmaceutical company developing potentially transformative long-acting therapies for ocular diseases including wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), retinal vein occlusion (RVO), and primary open angle glaucoma (POAG), today announced the initiation of its Phase 2a study with GB-102 in patients with macular edema (ME) secondary to DME or RVO.

Focus Is on Medical Technology Companies Addressing Non-Communicable Diseases in Low-Resource Settings